Abstract P141: Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitorJoshua A. Ballard, Steven W. Andrews, David Abraham et al.|Molecular Cancer Therapeutics|2021Cited by 11